CRUCIAL MARKERS SHOWING THE RISK OF CORONARY ARTERY DISEASE IN OBESITY: ADMA AND NEOPTERIN

Basit Öğe Kaydı
dc.contributor.authorAvci, Emre
dc.contributor.authorKarabulut, Alpaslan
dc.contributor.authorAvci, Avci Alp
dc.contributor.authorBaba, Burcu
dc.contributor.authorBilgi, Cumhur
dc.date.accessioned2021-11-01T15:03:10Z
dc.date.available2021-11-01T15:03:10Z
dc.date.issued2020
dc.department[Belirlenecek]
dc.description.abstractBackground: Obesity is responsible for high morbidity and mortality, both in developed and developing countries. It is associated with many chronic and metabolic diseases. Asymmetric dimethylarginine (ADMA) has been demonstrated to be a biomarker of endothelial dysfunction in humans and increased ADMA associated with cardiovascular disease (CVD) risk has been reported in many states. Neopterin (NP) produced by monocytes/macrophages in response to stimulation by interferon-gamma (IFN-gamma) is emphasized in recent findings. The current study aims to investigate ADMA and NP levels which may assume a role in guiding the early diagnosis of coronary artery disease in obesity. Methods: This is an original research study in which ADMA and NP levels of 50 patients (25 male/25 female) diagnosed with obesity were compared with those of 30 healthy individuals (15 male/15 female) as control. The high-performance liquid chromatography (HPLC) method was used while determining parameters. Results: ADMA and NP levels in obese individuals were found to be significantly higher than in those enrolled in the control. ADMA values were found to be higher in obese subjects (0.71 +/- 0.24 mu mol/L) as compared with levels found in healthy subjects (0.58 +/- 0.16 mu mol/L) (p<0.05). A significant increase of serum neopterin levels was found in obese subjects (8.8 +/- 3.5 mu mol/L) as compared with controls (4.9 +/- 1.69 mu mol/L) (p<0.05). Also, there was a strong positive correlation between NP and ADMA values in obese individuals (r=0.954). Conclusions: Our study revealed that obese subjects have higher ADMA and neopterin levels. These results demonstrated that both ADMA and NP levels may be potential risk factors for coronary heart disease in obesity.
dc.identifier.doi10.5937/jomb0-24683
dc.identifier.endpage459en_US
dc.identifier.issn1452-8258
dc.identifier.issn1452-8266
dc.identifier.issue4en_US
dc.identifier.pmid33312061
dc.identifier.scopus2-s2.0-85099144594
dc.identifier.scopusqualityQ3
dc.identifier.startpage452en_US
dc.identifier.urihttps://doi.org/10.5937/jomb0-24683
dc.identifier.urihttps://hdl.handle.net/11491/7005
dc.identifier.volume39en_US
dc.identifier.wosWOS:000575084800006
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthor[Belirlenecek]
dc.language.isoen
dc.publisherSoc Medical Biochemists Serbia
dc.relation.ispartofJournal Of Medical Biochemistry
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectobesityen_US
dc.subjectasymmetric dimethylarginineen_US
dc.subjectneopterinen_US
dc.subjectendothelial dysfunctionen_US
dc.titleCRUCIAL MARKERS SHOWING THE RISK OF CORONARY ARTERY DISEASE IN OBESITY: ADMA AND NEOPTERIN
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu